Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338936
Status:
COMPLETED
Last Update Posted:
2011-11-08
First Post:
2006-06-16
Brief Title:
Long Term Study of VAH631 in Patients With Essential Hypertension Extension From B1303 Study
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 Valsartan and Hydrochlorothiazide Combined and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension Extension From B1303 Study -
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH VAL HCTZ 40625mg and 80125mg in essential hypertensive patients The 350 patients approximately who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None